Product overview

As a B cell lineage marker, CD19 is expressed from the early pro-B cell stage to the B cell lymphoblast stage; however, CD19 is down-regulated as B cells mature to plasma cells. The CD19 antigen is also expressed on most malignant B cells and on a subset of follicular dendritic cells.
The CliniMACS® CD19 Product Line consists of murine anti-CD19 monoclonal antibodies conjugated to superparamagnetic iron dextran particles.
One vial contains 7.5 mL sterile, non-pyrogenic solution.
The performance of the CliniMACS CD19 Product Line depends on the individual separation strategy. For information on respective capacities, refer to the

Related products for
CliniMACS
®
CD19 Product Line

1 products available